Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma

British Journal of Cancer, Published online: 07 October 2020; doi:10.1038/s41416-020-01092-0Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

CONCLUSION: We present a new instrument targeting pathologies with p-VHL/HIF altered function that impact the PD-L2 expression through the change in transcriptional, growth factors, and AKT/mTOR modulation.PMID:34563045 | DOI:10.3390/cimb43020076
Source: Mol Biol Cell - Category: Molecular Biology Authors: Source Type: research
Cancers, Vol. 13, Pages 4801: Therapeutic Effects of Inhibition of Sphingosine-1-Phosphate Signaling in HIF-2α Inhibitor-Resistant Clear Cell Renal Cell Carcinoma Cancers doi: 10.3390/cancers13194801 Authors: Rouven Hoefflin Sabine Harlander Behnaz A. Abhari Asin Peighambari Mojca Adlesic Philipp Seidel Kyra Zodel Stefan Haug Burulca Göcmen Yong Li Bernd Lahrmann Niels Grabe Danijela Heide Melanie Boerries Anna Köttgen Mathias Heikenwalder Ian J. Frew Specific inhibitors of HIF-2α have recently been approved for the treatment of ccRCC in VHL disease patients and...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
CONCLUSION: In a large, multi-institutional cohort of patients undergoing surgery for non-metastatic RCC with tumor thrombus, thrombus extent was not independently associated with recurrence or death.PMID:34556430 | DOI:10.1016/j.urolonc.2021.08.016
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Source Type: research
Conclusions: This retrospective study points out that early systemic steroids administration to manage irAEs might not have a detrimental effect on patient clinical outcome in NSCLC, melanoma and RCC patients.
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
CONCLUSIONS: Adding SAbR did not improve the response rate to HD-IL-2 in patients with mRCC in this study. Tissue analyses suggest a possible correlation between frameshift mutation load as well as tumor immune infiltrates and clinical outcomes.PMID:34551906 | DOI:10.1158/1078-0432.CCR-21-2083
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Aging (Albany NY). 2021 Sep 23;13(undefined). doi: 10.18632/aging.203564. Online ahead of print.ABSTRACTRenal cell carcinoma (RCC) is a lethal malignancy of the genitourinary system. Follistatin-like 3 (FSTL3), which mediates cell differentiation and growth, acts as a biomarker of tumors and participates in cancer development and progression. Presently, the FSTL3's functions in RCC were investigated. Quantitative reverse transcription PCR (qRT-PCR), Western Blot, and enzyme linked immunosorbent assay (ELISA) were conducted to verify FSTL3 expression in RCC tissues and cell lines. BrdU assay and CCK8 experiment were made to...
Source: Aging - Category: Biomedical Science Authors: Source Type: research
PTP4A3 plays an important role in the tumorigenesis and metastasis of multiple tumors, but its prognostic role in renal cancer is not well understood. We utilized the Oncomine and Tumor Immunoassay Resource databases to examine the differential expression of PTP4A3 in tumor tissues and normal tissues in breast, urinary tract, gastrointestinal tract and skin. Using the GEPIA and PrognoScan databases, the independent prognostic role of PTP4A3 was confirmed in clear cell renal cell cancer and papillary renal cell cancer. Expression of PTP4A3 were obviously higher in tumor tissue compare with normal tissues (P=0.028). We haven...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusion: The highly standardized analysis of a broad range of cancers identified a ranking order of tumors according to their relative prevalence of MUC5AC expression.PMID:34547930 | DOI:10.1177/15330338211043328
Source: Technology in Cancer Research and Treatment - Category: Cancer & Oncology Authors: Source Type: research
In conclusion, NS398 is a potential therapeutic agent for ADPKD.PMID:34551202 | DOI:10.1111/jcmm.16903
Source: J Cell Mol Med - Category: Molecular Biology Authors: Source Type: research
Conclusion: The highly standardized analysis of a broad range of cancers identified a ranking order of tumors according to their relative prevalence of MUC5AC expression.PMID:34547930 | DOI:10.1177/15330338211043328
Source: Cell Research - Category: Cytology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | UK Health